Details of the Drug

General Information of Drug (ID: DMWZO21)

Drug Name
FP-187
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Approved [1]
Secondary progressive multiple sclerosis N.A. Approved [1]
Autoimmune diabetes 5A10 Phase 2 [2]
Cross-matching ID
PubChem CID
637568
ChEBI ID
CHEMBL2107333
TTD ID
D00ICY
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
2 ClinicalTrials.gov (NCT01230138) Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis. U.S. National Institutes of Health.